Clinical trials are the most reliable – and ultimately the fastest – way to translate promising laboratory science into new and better ways to treat and care for people living with ALS.

Launched in 2021, our Clinical Trial Awards help stimulate the development of new and improved therapies for ALS by providing up to $1,000,000 over 2 or 3 years to support early-stage clinical trials. These trials produce data on safety, dosing and biomarkers that are essential for moving an investigational therapy one step closer to being evaluated by the FDA. Positive results at this stage also “de-risk” the next stage of drug development, typically large clinical trials, and help attract the follow-on funding necessary to complete this work.